vs
Side-by-side financial comparison of Bolt Biotherapeutics, Inc. (BOLT) and MESABI TRUST (MSB). Click either name above to swap in a different company.
MESABI TRUST is the larger business by last-quarter revenue ($3.6M vs $2.5M, roughly 1.4× Bolt Biotherapeutics, Inc.). MESABI TRUST runs the higher net margin — 77.1% vs -265.2%, a 342.3% gap on every dollar of revenue. Over the past eight quarters, MESABI TRUST's revenue compounded faster (-24.1% CAGR vs -31.2%).
Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company specializing in immune-stimulating antibody conjugate (ISAC) therapies for cancer treatment. Its core pipeline targets hard-to-treat solid tumors, serving global oncology markets and advancing novel immunotherapies that trigger targeted anti-tumor immune responses to improve patient outcomes.
Mesabi Trust is a United States-based royalty trust that holds permanent royalty interests in iron ore mining properties located in Minnesota's Mesabi Range. It earns revenue primarily from royalty payments tied to the production and sale of iron ore products, with core earnings sourced from active mining partners operating on the land it holds interests in, catering to the global steel manufacturing market.
BOLT vs MSB — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $2.5M | $3.6M |
| Net Profit | $-6.6M | $2.8M |
| Gross Margin | — | 77.1% |
| Operating Margin | -283.4% | — |
| Net Margin | -265.2% | 77.1% |
| Revenue YoY | — | -95.5% |
| Net Profit YoY | 58.4% | -96.5% |
| EPS (diluted) | $-9.38 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.5M | $3.6M | ||
| Q3 25 | $2.2M | $5.6M | ||
| Q2 25 | $1.8M | $4.7M | ||
| Q1 25 | $1.2M | $6.9M | ||
| Q4 24 | $0 | $79.0M | ||
| Q3 24 | $1.1M | $6.5M | ||
| Q2 24 | $1.3M | $6.3M | ||
| Q1 24 | $5.3M | $6.2M |
| Q4 25 | $-6.6M | $2.8M | ||
| Q3 25 | $-7.1M | $4.7M | ||
| Q2 25 | $-8.6M | $3.6M | ||
| Q1 25 | $-11.0M | $6.1M | ||
| Q4 24 | $-15.9M | $78.3M | ||
| Q3 24 | $-15.2M | $5.4M | ||
| Q2 24 | $-21.2M | $3.5M | ||
| Q1 24 | $-10.8M | $4.7M |
| Q4 25 | — | 77.1% | ||
| Q3 25 | — | 84.6% | ||
| Q2 25 | — | 76.7% | ||
| Q1 25 | — | 88.5% | ||
| Q4 24 | — | 99.1% | ||
| Q3 24 | — | 83.2% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 75.3% |
| Q4 25 | -283.4% | — | ||
| Q3 25 | -355.1% | — | ||
| Q2 25 | -510.5% | — | ||
| Q1 25 | -991.4% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -1441.1% | — | ||
| Q2 24 | -1772.3% | — | ||
| Q1 24 | -324.1% | — |
| Q4 25 | -265.2% | 77.1% | ||
| Q3 25 | -329.4% | 84.6% | ||
| Q2 25 | -474.6% | 76.7% | ||
| Q1 25 | -903.4% | 88.5% | ||
| Q4 24 | — | 99.1% | ||
| Q3 24 | -1330.1% | 83.2% | ||
| Q2 24 | -1662.4% | 55.7% | ||
| Q1 24 | -205.0% | 75.3% |
| Q4 25 | $-9.38 | — | ||
| Q3 25 | $-3.72 | — | ||
| Q2 25 | $-4.46 | — | ||
| Q1 25 | $-0.29 | — | ||
| Q4 24 | $-13.73 | — | ||
| Q3 24 | $-7.93 | — | ||
| Q2 24 | $-11.12 | — | ||
| Q1 24 | $-0.28 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $27.5M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $26.5M | $21.1M |
| Total Assets | $56.7M | $26.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $27.5M | — | ||
| Q3 25 | $31.9M | — | ||
| Q2 25 | $34.8M | — | ||
| Q1 25 | $38.8M | — | ||
| Q4 24 | $47.3M | — | ||
| Q3 24 | $53.8M | — | ||
| Q2 24 | $73.7M | — | ||
| Q1 24 | $91.3M | — |
| Q4 25 | $26.5M | $21.1M | ||
| Q3 25 | $32.1M | $22.8M | ||
| Q2 25 | $38.8M | $19.6M | ||
| Q1 25 | $46.8M | $23.3M | ||
| Q4 24 | $57.2M | $95.3M | ||
| Q3 24 | $72.0M | $22.1M | ||
| Q2 24 | $85.9M | $20.7M | ||
| Q1 24 | $104.2M | $21.0M |
| Q4 25 | $56.7M | $26.0M | ||
| Q3 25 | $65.1M | $24.8M | ||
| Q2 25 | $75.5M | $27.4M | ||
| Q1 25 | $85.9M | $101.7M | ||
| Q4 24 | $99.6M | $100.7M | ||
| Q3 24 | $109.3M | $26.2M | ||
| Q2 24 | $124.2M | $25.1M | ||
| Q1 24 | $142.9M | $26.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-7.2M | $3.5M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | 1.27× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-7.2M | $3.5M | ||
| Q3 25 | $-9.7M | $4.4M | ||
| Q2 25 | $-9.6M | $2.1M | ||
| Q1 25 | $-13.4M | $93.9M | ||
| Q4 24 | $-14.4M | $78.2M | ||
| Q3 24 | $-14.0M | $3.8M | ||
| Q2 24 | $-16.1M | $2.5M | ||
| Q1 24 | $-16.8M | $14.6M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-14.0M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -1227.6% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.6% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.0% | — |
| Q4 25 | — | 1.27× | ||
| Q3 25 | — | 0.92× | ||
| Q2 25 | — | 0.57× | ||
| Q1 25 | — | 15.48× | ||
| Q4 24 | — | 1.00× | ||
| Q3 24 | — | 0.71× | ||
| Q2 24 | — | 0.72× | ||
| Q1 24 | — | 3.11× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
